Creatine for Older Adults: Muscle, Brain, and Bone

Sensitive populations: This article references menopausal. Always confirm any supplement change with your gynecologist before starting — dosing, contraindications, and risk profile shift in these groups.

Creatine monohydrate has been studied for gym performance for decades, but the strongest case for taking it after 60 is muscle and, more cautiously, cognition. Adults lose roughly 3 to 8% of muscle mass per decade, and brain creatine content falls with age. Randomized trials of creatine plus resistance training improve lean mass and strength. They have not shown a bone-density benefit in the pooled postmenopausal trials.

Sarcopenia: Creatine’s Primary Target in Aging

Adults gradually lose muscle mass with age — estimates from imaging studies suggest roughly 3 to 8% per decade after age 30, accelerating after 60. The same trend shows up as falling strength and function and is one of the drivers of frailty, fall risk, and loss of independence. Several meta-analyses have shown that creatine supplementation combined with resistance training in older adults produces greater gains in lean mass and strength than resistance training plus placebo. Devries and Phillips’ 2014 meta-analysis pooled trials in adults over about 50 and reported additional lean mass gains on the order of about 1.3 kg with creatine plus training. Without formal resistance training the additional benefit is smaller, but the combination is consistently the best-supported intervention.

Brain Health: The Emerging Evidence

The brain uses phosphocreatine to rapidly regenerate ATP during cognitive demand. Older adults tend to have lower brain creatine content than younger adults on magnetic resonance spectroscopy. Several short-term RCTs have found that creatine supplementation improves performance on memory and processing-speed tasks, particularly under conditions of cognitive stress (sleep deprivation, hypoxia, or in older participants). The Avgerinos 2018 systematic review found a consistent positive signal for memory in healthy older adults, with smaller or null effects in young, well-rested participants. Whether these short-term cognitive effects translate into reduced dementia risk over long timescales is not yet established, but the mechanistic logic and short-term data are encouraging.

Bone Density: Not a Pooled Benefit

A single 12-month trial is often cited for bone. Chilibeck and colleagues gave postmenopausal women on a supervised resistance-training program 0.1 g/kg/day creatine and reported slower loss of femoral-neck bone mineral density than placebo (PMID 25386713). Trials in older men have been more mixed. That is not what the pooled estimate shows. A 2026 systematic review of postmenopausal women (Naddafha et al., 7 RCTs, 608 randomized; PMID 42141930, doi:10.1080/15502783.2026.2668435) found bone mineral density unchanged overall, and the authors say any bone effect remains unclear. The same review found a lean-mass mean difference of +0.37 kg (95% CI +0.05 to +0.69; 5 trials, 338 participants) and a leg-press mean difference of +7.5 kg (95% CI +2.2 to +12.8; 3 trials, 111 participants). Those gains showed up when creatine was at least 5 g/day and combined with resistance training. Trials using 3 g/day or less without resistance training showed no measurable effect. The review was not prospectively registered, and one author chairs a creatine advisory board supported by a creatine manufacturer.

The dose for healthy aging is well-established: 3 to 5 g of creatine monohydrate daily, with no loading phase required. Creatine monohydrate is the form with the largest evidence base; expensive alternative forms (creatine HCL, buffered creatine) have not been shown to be more effective. People with significant kidney disease should discuss creatine with their clinician before starting, since creatine modestly raises serum creatinine via non-pathologic pathways.